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ORIGINAL ARTICLEFocal Liver Lesion Classification and Characterization
in Noncirrhotic Liver: A Prospective Comparison
of Diffusion-Weighted Magnetic
Resonance–Related ParametersStefano Colagrande, MD* Francesco Regini, MD* Filippo Pasquinelli, MD* Lorenzo Nicola Mazzoni, MS†
Francesco Mungai, MD* Antonella Filippone, MD‡ and Luigi Grazioli, MD§Purpose: The objective of this study was to prospectively verify if
diffusion-weighted magnetic resonance (DwMR)–related parameters
such as perfusion fraction ( f ) and slow diffusion coefficient (D),
according to Le Bihan theory, are more effective than apparent diffu-
sion coefficient (ADC) for classification and characterization of the more
frequent focal liver lesions (FLLs) in noncirrhotic liver.
Methods: Sixty-seven patients underwent standard liver magnetic
resonance imaging (MRI) and free-breath multi-b DwMR study. Two
regions of interest were defined by 2 observers, including 1 FLL for
each patient (21 hemangiomas, 21 focal nodular hyperplasias, 25 me-
tastases) and part of surrounding parenchyma, respectively. For every
FLL,D, f, and ADC were estimated both as absolute value and as ratio be-
tween FLL and surrounding parenchyma by fitting the reduced equation
of the bicompartmental model to experimental data; t test, analysis of
variance, and receiver operating characteristic analysis were performed.
Results: t Test showed significant differences in ADClesion, flesion,Dlesion,
ADCratio, andDratio values between benign and malignant FLLs, more pro-
nounced for ADClesion (P < 0.0009) and ADCratio (P = 0.001). Applying
cutoff values of 1.55 × 10−3 mm2/s (ADClesion) and 0.89 (ADCratio), the
DwMR study presented sensitivities and specificities, respectively, of
84% and 80% (for ADClesion), 72% and 80% (ADCratio).
Conclusions: Apparent diffusion coefficient (by fitting procedures)
better performs than do D and f in FLL classification, especially when
its values are less than 1.30 or greater than 2.00 × 10−3 mm2/s.
Key Words: focal liver lesion, diffusion-weighted imaging, apparent
diffusion coefficient (ADC), slow diffusion coefficient (D), perfusion
fraction (f), IVIM theory
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D iffusion-weighted magnetic resonance (DwMR) imaging isan attractive technique that can potentially add useful qual-
itative and quantitative information to conventional imaging.
It is quick (performed within a breath hold or by free breath
acquisition) and can be easily incorporated into existing pro-
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Copyright © 2013 Lippincott Williams & Wilkins. Unauadministration; thus, it is easy to repeat and useful in patients
with severe renal dysfunction.1–5
The use of liver DwMR was initially promising for both
detection and classification of focal liver lesions (FLLs),6 and
it is now potentially useful for an early response evaluation after
chemotherapy in oncologic patients.7–13 Although capability in
detecting FLLs has been confirmed by various studies,6,7,14–17
the results regarding the utility of DwMR in FLL classification
are contradictory.
Nowadays, it is still unclear whether these challenging con-
clusions depend on acquisition/postprocessing methods rather
than on a physiological low specificity of this technique.18,19
As far as we know, these results were commonly based on eval-
uation of apparent diffusion coefficient (ADC) values, which
are lower in malignant FLLs than in benign ones, although with
wide overlap between the 2 groups.6,19,20–24
However, DwMR can provide estimations of other para-
meters according to the intravoxel incoherent motion (IVIM)
theory of Le Bihan et al,25,26 such as slow diffusion coefficient
(D) and perfusion fraction ( f ). Moreover, in the aforesaid stud-
ies, the ADC values were always calculated in the FLLs without
any comparison to the surrounding parenchyma.
Given this background, the aim of our prospective study
was to compare the performances of ADC, D, and f, both as
absolute value and as ratio to surrounding liver parenchyma,
for classification/characterization of the more frequent FLLs
in patients with no cirrhosis.
MATERIALS AND METHODS
This prospective single-center study, approved by institu-
tional review board (October 18, 2010) was conducted at the
University Hospital of (blinded). The study complied with the
terms of the Declaration of Helsinki (revision of Edinburgh,
2000).27 Written consent was obtained from all patients before
the examination.
Patients and Study Design
From June 2011 to May 2012, patients with no cirrhosis,
who came to our radiology unit for follow-up, with known non-
cystic FLL(s), were prospectively assessed for eligibility.
The inclusion criterion was the presence of at least 1 hem-
angioma, focal nodular hyperplasia (FNH) or metastases, mea-
suring no less than 2 cm in maximum diameter and located in
the central-lower part of the right liver lobe (where data show
higher reproducibility).18 The exclusion criteria were as fol-
lows: underage, history of illegal drug use or alcohol abuse,
diffuse liver disease,28 abnormal liver function tests, and his-
tory of liver surgery or interventional liver treatment.
Reference Standard
In this study, the reference standard29 was the combination
of clinical anamnesis and results from previous imaging studiesomput Assist Tomogr • Volume 37, Number 4, July/August 2013
thorized reproduction of this article is prohibited.
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puted tomography, biopsy).
All the patients with malignancy received histological con-
firmation. A full biopsy was performed on the nodule selected
for analysis or, if multiple, on a nodule with equivalent imaging
pattern. If a patient presented both malignant and benign nodules,
only the malignant one was considered, if suitable.
Hemangiomas were defined on computed tomography/MRI
typical signal characteristics and contrast enhancement pattern:
high and homogeneous signal intensity (SI) on heavily T2-
weighted acquisitions (echo time >250 milliseconds) and globu-
lar enhancement showing SI similar to that of vessels in every
dynamic phase.30,31
Focal nodular hyperplasias were diagnosed on unenhanced
MRI as being quite isointense to the surrounding parenchyma
on T2- and in-phase T1-weighted images, without SI dropout on
out-of-phase T1-weighted images. After liver-specific gadolinium
chelates contrast agent administration, the diagnostic patterns
were hypervascular on arterial phase, without washout on por-
tal and equilibrium phase, and isointense/slight hyperintense
to the surrounding parenchyma on biliary phase.32,33 The cen-
tral scar is usually seen in nodule larger than 3 cm and appears
hypointense and hyperintense with respect to the surrounding
parenchyma on unenhanced T1- and T2-weighted images, re-
spectively, with enhancement on portal/equilibrium phase.Magnetic Resonance Imaging
Magnetic resonance imaging of the liver was performed
using a 1.5-T magnetic resonance body scanner (Gyroscan
NT Intera Release 12; Philips, Eindhoven, the Netherlands; max-
imum gradient strength 30 mT/m, peak slew rate 120 mT/m per
millisecond) equipped with a 4-channel receiver coil, positioned
to cover the upper abdomen of the subject lying in a supine position;
the arms were extended over the head to reduce artifacts. All
examinations were performed on patients fasting for 6 hours.
Magnetic resonance imaging protocol included the follow-
ing sequences (Table 1): breath-hold transverse T1-weighted
gradient-echo in- and out-of-phase, free-breath transverse and
coronal T2-weighted turbo spin-echo, transverse diffusion-
weighted free-breath multi-b, dynamic 3-dimensional volumetric
interpolated breath-hold T1-weighted before and after injection
of 0.1 mL per kilogram of GD-EOB-DTPA (gadolinium ethoxy-
benzyl diethylenetriamine pentaacetic acid, Primovist; BayerTABLE 1. Sequence Details
Sequence
TR/TE,ms/Flip
Angle, degrees NSA M
T1-weighted 2-dimensional gradient echo
in-/out-of-phase
184/4.6–2.3/80 1 19
T2-weighted single-shot turbo spin-echo
(SSH)
∞/80/90 1 26
T1-weighted 3-dimensional gradient echo
(THRIVE)*
3.5/1.6/10 1 16
DwI SSH EPI† 2000/66/90 2 12
All sequences were acquired with parallel imaging SENSE factor 1.5, b
to software limitation (Philips Intera, release 12.1).
*THRIVE (T1-weighted high-resolution isotropic volume examination) s
second intervals after contrast agent and at 20 minutes during hepatobiliary
†Five b values: 0, 200, 400, 600, and 800 s/mm2.
TR, repetition time; TE, echo time; NSA, number of signal averages; TA
EPI, echo-planar imaging.
© 2013 Lippincott Williams & Wilkins
Copyright © 2013 Lippincott Williams & Wilkins. UnauHealthcare, Leverkusen, Germany) also repeated during hepato-
biliary phase (at least 20 minutes after the injection).
DwMR Parameters—Diffusion-Related Quantities
DwMR data acquired with different D weightings were
processed through the reduced version of the 2 compartments
model of IVIM theory,26
Sb=S0 ¼ 1−fð Þ exp −b Dð Þ (1)
Sb/S0 is the ratio between the signal obtained with b ≠ 0
and b = 0, f is the perfusion fraction, and D, the slow diffusion
coefficient.25,36–38 f And Dwere estimated by fitting Eq. 1 to SI
data obtained at different b values (from 200 to 800 s/mm2).
This model was adopted considering the absence of data
obtained with b values lower than 150 s/mm2 (b = 0 data were
excluded): over this threshold, the influence of IVIM from per-
fusion is reasonably negligible, and monoexponential signal
decay is expected. The use of this reduced model implies that
fast diffusion coefficient (D*, primarily involved in SI varia-
tions between b = 0 and 200 s/mm2) was not calculated.25,26,33–36
Apparent diffusion coefficient was estimated with a similar pro-
cedure, fitting the following equation to SI data obtained at differ-
ent b values (from 0 to 800 s/mm2):
Sb=S0 ¼ exp −b ADCð Þ (2)
The main difference between the first and the second fitting
procedure is that b = 0 data are used only for ADC estimation
(Eq. 1). All calculations were performed using semiautomatic
homemade software driving the nonlinear regression algorithms
provided in Gnuplot (http://www.gnuplot.info/, 4.4.2 release).
Sampling Method and Diffusion-Weighted
Images Analysis
The sampling of FLL was performed with freehand-drawn
region of interest (ROI) inscribing the entire lesion and avoid-
ing lesion boundary, necrotic areas, and vessels. Region of in-
terest was defined on b = 0 images and then copied over all
other D-weighted images using ImageJ.38 In case of multiple
FLLs in the medium-lower part of the right lobe, the one showing
the highest diffusion-weighted signal homogeneity at visualatrix FOV, mm
Slice Thickness,
mm/n
Bandwidth,
Hz/pixel TA, s
2 × 110 280–400 6/24 1002 17
8 × 150 290–415 4/48 518 120/180
4 × 114 285–400 1.5/80 530 18
8 × 65 300–420 7/12 1555 140
ut diffusion-weighted images were obtained without SENSE factor due
equences were performed before and repeated 3 times at 30-, 70-, 180-
phase.
, acquisition time; FOV, field of view; DwI, diffusion-weighted imaging;
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FIGURE 1. Flowchart for patient selection.
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was chosen.
For every FLL, an ROI of similar size was drawn in the
adjacent healthy liver parenchyma, excluding large blood
vessels, biliary vessels, and hepatic borders, to calculate
diffusion-weighted–related parameters not only as absolute
values (flesion, Dlesion, ADClesion) but also as ratios to normal
parenchyma ( flesionfparenchyma ,
Dlesion
Dparenchyma
, and ADClesionADCparenchyma ) reported in
the following as fratio, Dratio, and ADCratio, respectively). This
was done to obtain more reproducible results and decrease the
dependence from b value. Every lesion and surrounding paren-
chyma received 3 measurements, and values were averaged.
Diffusion-weighted images and ROI shapes were evaluated in
consensus by a radiologist and a physicist (F.R and L.N.M.)
and then finally checked by the study coordinator (S.C.). When
they expressed discordant opinions about a value of one of the
estimated parameters (>5% difference), they reached a consen-
sus through a joint review.
We checked the stability of our scanner by doing an DwMR
phantom study,18 as recommended.34 The phantom was scanned
10 times during the period of the study, applying a diffusion-
weighted sequence b = 0 − 1000 s/mm2 (with steps of 100 s/mm2).
Apparent diffusion coefficient was calculated by fitting Eq. 2
to the acquired data. The ADC variation with respect to base-
line was estimated.Statistical Analysis
Levene test was performed on each of the 6 variables
(flesion, Dlesion, ADClesion, fratio, Dratio, ADCratio), to evaluate
the homogeneity of variance among the various histotypes
(hemangioma, FNH, metastasis). Analysis of variance (ANOVA)
was performed on the same variables, to evaluate differences
among the mean values of the 3 different groups. In case of sig-
nificant differences, detected by ANOVA, Games-Howell and
Bonferroni post hoc tests were applied, respectively, in case562 www.jcat.org
Copyright © 2013 Lippincott Williams & Wilkins. Unauof significant or nonsignificant differences among groups vari-
ance, revealed by Levene test (significance threshold was
set at P < 0.05). Descriptive statistic was also calculated for
each group.
t Test for independent groups was performed to establish dif-
ferences between benign and malignant lesions, assuming or not
the agreement of variance depending on Levene test results. After-
ward, a receiver operating characteristic (ROC) analysis was per-
formed, calculating the areas under the curve for each variable.
All the latter values were subsequently compared, to identify
the set of DwMR parameters most useful in differentiating
and identifying benign and malignant FLLs, excluding from
further analysis those parameters showing significant differences
from the best one (statistical significance was set at P < 0.05).
Finally, sensitivity and specificity for malignancy were cal-
culated on the whole spectrum of values of the selected best vari-
ables. Sensitivity represents the percentage of malignant lesions
that the test variable identifies as malignant, whereas specificity
represents the percentage of benign lesions that the test variable
identifies as benign. Statistical analysis was performed using
STATA 10.2 (Stata Corp, College Station, Tex).RESULTS
One-hundred thirty consecutive patients were assessed for
eligibility. Sixteen patients were excluded because of not satis-
fying the magnetic resonance compatibility criteria or because
the presence of a solid FLL could not be confirmed with stan-
dard MRI. Subsequently, 47 patients were excluded because
of not satisfying the inclusion criteria and because of standard
MRI findings.
Therefore, the final cohort included 67 patients (43 men,
24 women; mean age, 58.5 years; age range, 27–81 years).
There were 25 patients with history of primary malignancy: co-
lon cancer (n = 10), breast cancer (n = 8), gastric cancer (n = 4),
and pancreatic cancer (n = 3). We finally studied 42 benign© 2013 Lippincott Williams & Wilkins
thorized reproduction of this article is prohibited.
TABLE 2. Mean ± SD and CV of Diffusion-Weighted Imaging–Related Parameters for Each Group of FLLs
Parameters HE FNH MTX
flesion 20 ± 12 (60) 22 ± 13 (59) 13 ± 7 (54)
Dlesion 1.53 ± 0.54 (35) 1.25 ± 0.39 (32) 1.05 ± 0.41 (39)
ADClesion 2.24 ± 0.96 (43) 1.86 ± 0.42 (23) 1.31 ± 0.47 (36)
fratio 0.66 ± 0.27 (41) 0.65 ± 0.25 (38) 0.44 ± 0.16 (36)
Dratio 1.45 ± 0.46 (32) 1.13 ± 0.39 (35) 1.02 ± 0.44 (43)
ADCratio 1.21 ± 0.46 (38) 1.05 ± 0.23 (22) 0.79 ± 0.26 (33)
Mean ± SD and coefficient of variation (CV, %) in brackets of perfusion fraction (f, %), diffusion coefficient (D, in ×10−3 mm2/s), ADC of the
lesion (in ×10−3 mm2/s), and corresponding ratios with healthy liver parenchyma measurements.
HE, hemangioma; MTX, metastasis.
J Comput Assist Tomogr • Volume 37, Number 4, July/August 2013 DwMR Parameter in Liver Lesion Classification(21 hemangiomas and 21 FNHs) and 25 malignant FLLs (me-
tastases) (Fig. 1), all of them situated in the medium-lower
part of the right lobe. Mean diameter of lesions was 2.7 cm
(range, 2–4.8 cm).
Our scanner showed good stability, comparable with what
has already been reported18: repeatability- and reproducibility-
related errors were always less than 0.8%.37
Subgroups: Characterization
Levene test established significant differences among groups
for flesion, ADClesion, and ADCratio variances so Bonferroni or
Games-Howell post hoc tests were consequently adopted. For
each group, mean and SD of flesion, Dlesion, ADClesion, fratio, Dratio,
and ADCratio are reported (Tables 2 and 3, Fig. 2). Analysis of
variance showed significant differences of Dlesion, ADClesion,
Dratio, and ADCratio among different groups (Table 4).
Benign Versus Malignant: Classification
Levene test established significant differences among groups
for the variance of flesion: for this variable, the hypothesis of dif-
ferent variances was adopted in the t test.
For each group, mean and SD of flesion, Dlesion, ADClesion,
fratio, Dratio, and ADCratio are reported. t Test showed significant
differences of flesion, Dlesion, ADClesion, Dratio, and ADCratio
among benign and malignant FLLs groups: corresponding
P values are reported (Table 2). The area under the curve of
the ROC analysis was maximum for ADClesion, and only ADCratio
showed nonsignificant difference with the former (P = 0.11,
Fig. 3): all other variables were excluded from further analysis.
Cumulative frequencies for these variables are reported (Fig. 4).
Sensitivity (with 95% confidence interval) corresponding
to a specificity of 80% was 84% (50%–97%) for ADClesion =
1.55 × 10−3 mm2/s and 72% (40%–92%) for ADCratio = 0.89.TABLE 3. Mean ± SD and CV of Diffusion-Weighted Imaging–Rel
Parameters Benign Lesions (B = HE + FNH)
flesion 20 ± 8 (40)
Dlesion 1.39 ± 0.49 (35)
ADClesion 2.05 ± 0.76 (37)
fratio 0.65 ± 0.22 (34)
Dratio 1.30 ± 0.45 (35)
ADCratio 1.13 ± 0.43 (38)
Mean ± SD and coefficient of variation (CV, %) in brackets of perfusion
lesion (in ×10−3 mm2/s), and corresponding ratios with healthy liver parench
© 2013 Lippincott Williams & Wilkins
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for various intervals of ADClesion values was calculated.
DISCUSSION
Our data brought good results in terms of statistically sig-
nificant differences between malignant and benign FLLs for
most of the parameters evaluated, either as absolute values or
as ratio, even if showing overlap between the 2 groups.
Many articles14,18,24 have shown the large variability of
the ADC in FLLs, which strongly depends on the b values
adopted.18 There are other parameters according IVIM theory,
which are less dependent on the choice of the b value acquisi-
tion, such as D and f. However, calculation of these parameters
is time-consuming in either acquisition (for a multi-b free-
breath sequence, at least 4 minutes is needed) or postproces-
sing (manual evaluation). Then we wondered if this additional
time and work would have been useful and if non–ADC-related
parameters would better perform than ADC itself in FLL clas-
sification characterization. To the best of our knowledge, this is
the first attempt to carry out this comparison even if other stud-
ies evaluated non–ADC-related parameters in normal and path-
ologic liver.39–41
The physiological interpretation, proposed for the first
time by Le Bihan et al,25,26,42 is that D represents the slow dif-
fusion coefficient, related to thermal diffusion of water mole-
cules, whereas f is the fraction of water molecules flowing
inside the capillary network. Both can be better estimated using
a series of diffusion-weighted images with b ≥ 200 s/mm2.
Le Bihan et al25,26,37,43 proposed another parameter used to
represent the influence of nondiffusional IVIM on DwMR sig-
nal: the coefficient D*, related to the random flow within capil-
lary network (fast motion). We did not evaluate it because it
was affected by a strong experimental error25,26,37,43 mainlyated Parameters for Benign and Malignant FLLs
Malignant Lesions (M = MTX) P, B vs M
13 ± 7 (54) 0.03
1.05 ± 0.41 (39) 0.004
1.31 ± 0.47 (36) <0.0009
0.44 ± 0.16 (36) 0.33
1.02 ± 0.44 (43) 0.02
0.79 ± 0.26 (33) 0.001
fraction (f, %), diffusion coefficient (D, in ×10−3 mm2/s), ADC of the
yma measurements. P value is given for benign versus malignant lesions.
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FIGURE 2. Mean values and SD of every parameter evaluated (flesion, Dlesion, ADClesion, fratio, Dratio, ADCratio) for each group of lesions
(hemangioma, FNH, metastasis). Levene test shows significant differences between hemangioma and metastasis for ADClesion,
Dlesion, ADCratio, and Dratio and between FNH and metastasis for ADClesion. l Indicates lesion; r, ratio.
Colagrande et al J Comput Assist Tomogr • Volume 37, Number 4, July/August 2013due to low b value acquisition and because adopting high
b values allows more accurate ADC estimation.
In our study, ADC performs better than do f and D. All
these parameters, in fact, show a significant difference between
benign and malignant lesions and between hemangiomas and
metastases, but only ADC values show significant differences
between FNHs and metastases. Within the group of benign FLLs,
there is no significant quantitative difference between FNH and
hemangioma.Malignant lesions show lower ADC, f, andD values
than benign lesion (Table 2). This could be due to the presence
of more restricted diffusion and lower perfusion within the
metastatic lesions.44 The best performances (higher sensitivity
and specificity) obtained with ADC parameter compared with
D and f probably relate to ADC features, being expression of
both perfusion- and diffusion-related motions.
Although there are quite good results in terms of signifi-
cant differences between malignant and benign FLLs, clinical
applications of DwMR-related parameters in FLL classificationTABLE 4. ANOVA Results
flesion Dlesion ADCles
Significant for NS Hemangioma vs
metastasis
(P = 0.002)
Hemangioma v
metastasis
(P < 0.0009
metastasis (P
Significant differences of all the diffusion-weighted imaging parameters e
different group of lesions and corresponding P values.
NS indicates not statistically significant.
564 www.jcat.org
Copyright © 2013 Lippincott Williams & Wilkins. Unauare in our opinion still limited, but not unhelpful at all. Quanti-
tative analysis could be used as added criterion together with a
qualitative DwMR analysis45 and other traditional sequences46;
this might be especially useful when contrast agent cannot be
administered. Moreover, even if our results show overlap be-
tween benign and malignant lesions, especially for ADC values
between 1.30 and 2.00 × 10−3 mm2/s (with 57% of benign
lesions and 35% of malignant ones within this range), ADC
values less than 1.30 × 10−3 mm2/s are most likely present in
metastases (only 5% of benign FLLs are below this threshold),
whereas ADC values greater than 2.00 × 10−3 mm2/s are rea-
sonably a sign of benignity (only 5% of metastases are over this
threshold) (Figs. 2–4). In our study, ADC is not calculated on
ADC maps obtained using SI ratio from only 2 images, with
and without D weighting (ie, b = 0 and b ≠ 0, respectively),
as usually performed automatically by commercial magnetic
resonance scanner. In a phantom showing monoexponential
signal decay, results obtained using these 2 methods are notParameter
ion fratio Dratio ADCratio
s
), FNH vs
= 0.001)
NS Hemangioma vs
metastasis
(P = 0.006)
Hemangioma vs
metastasis
(P = 0.001)
stimated in the lesion and as ratios with healthy liver parenchyma among
© 2013 Lippincott Williams & Wilkins
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FIGURE 3. ROC analysis. The area under the curve (AUC) of the ROC analysis was maximum for ADClesion (gray diamonds), and only
ADCratio (black circles) AUC showed nonsignificant difference with the former (P = 0.11).
FIGURE 4. Cumulative frequencies of ADCr (A) and ADCl (B) both for benign and malignant focal liver lesions.
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Colagrande et al J Comput Assist Tomogr • Volume 37, Number 4, July/August 2013different18; this is not true in the liver parenchyma, where a
biexponential signal decay is expected.25 In this case, the use
of the mentioned best-fitting procedure was performed in
ADC too, to achieve results comparable with f and D. Calcula-
tion brings results that are less dependent on SI at every b value
and should be then more accurate and reproducible,47 even if
time consuming.
The use of parameters as ratio brought no relevant contri-
bution to the value of DwMR in FLL characterization because
of the increased measurement error, as expected. However, in
our opinion, ratio could have some utility, further decreasing
the b dependency and allowing to better compare DwMR acqui-
sition performed with different b values. On this background, al-
though in the ratio evaluation the reference organ is usually the
spleen,48,49 in our assessment we preferred the adoption of the
adjacent hepatic parenchyma, to have the advantage of using
the same level of slice for ROI placement and consequently
the equivalent field heterogeneity. In fact, in our experience,
with a ratio greater than 1 or less than 0.8 the probability to re-
spectively have benignity or malignancy is around 90% (Fig. 4).
So, the evaluation is fast, simple, and reproducible, and this
could be useful in the everyday practice.
The main weakness of the study could be represented by
the few histotypes included using very selective enrollment cri-
teria. However, we chose this study design because we did not
need many different histotypes to achieve the proposed com-
parison among parameters. This study was planned to find
out what diffusion-weighted–related parameter and quantita-
tive method were the best (the more reproducible and the less
affected by artifacts on a scanner without navigator echo).
Our strategy was to perform the assessment in the best condi-
tions; thus, we had cared to avoid lesions too small to be sam-
pled, as well as those localized in the left lobe and/or at the
top/bottom of the liver, where artifacts are usually present.
Moreover, it would have been very difficult to enroll a group
of primary malignancies (hepatocellular carcinoma and cho-
langiocellular carcinoma) and of adenomas with a similar num-
ber of cases of the selected groups. Finally, mean ADC value of
adenoma is usually not dissimilar from that of FNH,45 whereas
values of hepatocellular carcinoma and cholangiocellular car-
cinoma are comparable to those of metastases.50
The great overlap between benign and malignant nodules
found in our and other series50 drives us to argue that in almost
half of the cases DwMR does not have the sensitivity to detect
the obvious difference in architecture, cellularity, and perfu-
sion among hemangioma, FNH, and metastases, even adopting
IVIM theory and non–ADC DwMR-related parameters. Then,
according to our series, ADC (absolute value and ratio) allows
for the best quantitative analysis. Further investigations should
be done to estimate differences in performance between fitted
ADC (non–b-related and time consuming) and nonfitted ADC
(b-related and not time consuming).
In conclusion, our results, by fitting procedure, show that
ADC as absolute value better performs than do D and f in
FLL classification and can be supportive in the diagnosis as
supplemental criterion of benignity or malignancy.REFERENCES
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